Schering-Plough Rebetron combination therapy
Executive Summary
Schering promoted interferon alfa/ribavirin combination therapy prior to approval, agency maintains in June 12 letter to the company. FDA cites materials disseminated at the Digestive Diseases Week in New Orleans May 16-22 that resembled "a package insert for the combination therapy," letters says. Rebetron was approved by FDA on June 5 ("The Pink Sheet" June 8, p. 15)